Animal Vaccine Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Animal Vaccine Market is Segmented By Product Type (Modified-live (attenuated) Vaccine, Inactivated (killed) Vaccine, Recombinant Vaccine, Toxoid Vaccine), By Animal Type (Companion Animal, Livestock Animal, Aquaculture), By Route of Administration (Subcutaneous, Intramuscular, Intranasal), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Animal Vaccine Market Size

The global animal vaccine market reached USD 12,089.2 million in 2022 and is projected to witness lucrative growth by reaching up to USD 22,404.3 million by 2030. The global animal vaccine market is expected to exhibit a CAGR of 8.2% during the forecast period (2023-2030). The global animal vaccine market trends show rising regulatory approvals for vaccines, owing to the rising prevalence of infectious diseases among animals and increasing research and development.

Furthermore, the numerous clinical trials, together with the rising demand for prevention of infections at the point of care, are driving up the animal vaccine market size. Due to the expansion of research in this field, the market is seeing an increase in demand from North American regions. With significant competitors like Ceva, Elanco, Zoetis Services LLC, and others actively operating in the market, the competition is driving the animal vaccine market growth.   

Animal Vaccine Market Scope

To know more Insights - Download sample

Animal Vaccine Market Dynamics and Trends

Increasing Innovation in Animal Vaccine Production Drive the Growth of the Animal Vaccine Market.

Over the anticipated timeframe, the animal vaccines market will likely be driven by the rising development in companion or aquaculture vaccine production around the world. Farm-raised fish might be protected with affordable, effective plant-based immunizations. 

A quick, effective, and preventative method of avoiding illnesses for fish is vaccination. Through the injection of vaccines, an animal's immune system is induced to produce a protective response. Vaccinations enhance the immune system's defenses of the animal and increase its capacity to resist illness when pathogens are encountered naturally. The antigens of pathogenic organisms that have undergone various processes to become non-pathogenic are used in vaccinations.

Numerous preliminary and clinical investigations have demonstrated the viability, effectiveness, and safety of producing vaccines in plants. The use of a plant-based platform can be advantageous for recombinant subunit vaccinations. Unlike live vaccines, plant-based vaccinations do not raise the same safety issues. 

Contrary to mammalian-based systems, undesirable or hazardous components such as bacterial toxins and undesired yeast proteins were not found in production methods originating from plants. The increasing innovation in animal vaccine production is a key factor in driving the growth of the global animal vaccines market.

Rising Government Initiatives and Novel Product Launches Creates Lucrative Opportunities  for Manufacturers

There is a growing animal vaccine market opportunity, owing to rising advancements and regulatory approvals due to the increasing prevalence of infectious diseases. The rising novel product launches by major key players is also an animal vaccine market trend driving the market. 

In June 2022, animal vaccines and other diagnostic kits created by the ICAR-National Research Centre on Equines, India, were introduced by Shri Narendra Singh Tomar, the Minister of Agriculture and Farmers' Welfare in the Union.

An inactivated (COVID-19) SARS-CoV-2 Delta vaccine for animals is the Ancovax Vaccine on Equines. The immunity induced by Ancovax neutralizes each of the Delta or Omicron Variants of SARS-CoV-2. The vaccine includes Alhydrogel as an adjuvant and inactivated SARS-CoV-2 (Delta) antigen. Dogs, lions, leopards, mice, and rabbits are all safe in it.

Complexity in Vaccine Production will Hamper the Growth of the Market

Developing vaccines is a difficult task. Even the simplest procedures might be challenging to carry out in order to create a vaccination that is reliable, consistent, and safe. Complex procedures must be established at a significant expense. The complexity is increased by the variation in the raw materials, the disease-causing agent itself, environmental factors, manufacturer competence, as well as fundamental production procedures. 

The intrinsic variability of many of the assays used to validate each stage is also quite significant. Failure to handle these risks may lead to vaccine failure and expensive vaccine recalls. The creation of several pathogens, including viruses and bacteria, is necessary for the development of both live attenuated or inactivated vaccines. As a result, there is a long delay between the commencement of manufacture and the delivery of the vaccine.   

Animal Vaccine Market Segment Analysis

The global animal vaccine market is segmented based on product type, animal type, route of administration and region.

Owing to Adoption, the Companion Animal Segment Accounted for Approximately 37.5% of the Animal Vaccine Market Share

Driving factors such as the rise of companion animals in the field of animal vaccines market is the rapidly growing adoption of companion animals all over the world. Vaccination is the cornerstone of preventing pets from a variety of illnesses, most of which are hard or impossible to treat. Despite the hazards they encounter daily from the environment, travel, and both direct and indirect interactions with sick or unvaccinated animals, pets benefit from the protection from disease. 

Every pet has unique risk factors, therefore, it's crucial to talk about these with the veterinarian so the best immunizations are given. The Summary of Product Characteristics (SPC) for each UK-authorized vaccination contains information about the various vaccines that is available to the general public. Companion animal vaccines are divided into two categories by the American Animal Hospital Association (AAHA): core and non-core vaccines. 

Although non-core vaccines are given depending on risk variables (geographic area and pet's lifestyle), core immunizations are advised for all cats and dogs. The first series of vaccinations for pets should be given to them between the ages of 6 and 8 weeks because the mother's milk's initial immunity is only effective for a few weeks. The companion animals offers significant opportunities for the animal vaccines market to expand their reach and customer base.

Source: DataM Intelligence Analysis (2023)

Animal Vaccine Market Geographical Share

North America Accounted for Approximately 39.8% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for animal vaccines for treatment purposes in healthcare, manufacturers in North America have a chance of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for animal vaccines. 

Increasing expenditure on healthcare and rising awareness among people, advancement of technologies for treatment, and increase in biopharmaceutical establishment across the region are also contributing to the growth of the animal vaccine market share of this region. 

The primary healthcare organizations and businesses' joint research endeavors as well as new product development that continuously aims to enhance available treatment options are also expected to contribute to the rising demand. Individuals are becoming more aware of various advanced techniques that are being studied for vaccine production leading to the expansion of the market in this region.

Source: DataM Intelligence Analysis (2023)

Animal Vaccine Market Companies

The major global players in the animal vaccine market include Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Services LLC, Ceva, Vetoquinol, Elanco, Veterquimica S.A., Phibro Animal Health Corporation, KBNP, Inc. and Kyoto Biken Laboratories, Inc. among others. 

COVID-19 Impact on Animal Vaccine Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global animal vaccine market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global animal vaccine market growth over the forecast period.

Key Developments

• In September 2022, a formal agreement was signed by Merck Animal Health, a part of Merck & Co., Inc., in which Merck Animal Health will purchase Vence from its founders and stockholders. Merck Animal Health is also referred to as MSD Animal Health in countries other than the United States and Canada. Vence is a pioneer in virtual fences for managing cattle and rotational grazing.
• In May 2022, Artemis Technologies, a producer of the oral rabies vaccine in Canada, was purchased by Ceva Santé Animale (Ceva). An oral rabies glycoprotein recombinant vaccine called ONRAB is created by Artemis in Guelph, Canada, and is approved for use on striped skunks (Mephitis mephitis) in that country. The substance was successfully used in field trials on wild skunks and raccoons in the USA.
• In January 2022, the U.S. Food and Drug Administration (FDA) granted approval for Solensia to help cats with osteoarthritis (OA) manage their pain, enhancing their comfort, mobility, and general well-being, according to a statement from Zoetis Inc. Solensia, a once-monthly injectable given in the veterinary clinic, prevents OA discomfort from interfering with the special relationship that cats have with their human companions.  

Why Purchase the Report?

• To visualize the global animal vaccine market segmentation based on product type, animal type, route of administration and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of animal vaccine market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global animal vaccine market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies